PDS Biotechnology Corporation (NASDAQ:PDSB) has a beta of 2.60. The stock’s Relative Strength Index (RSI) is 57.43, with weekly volatility at 14.64% and ATR at 1.66. The PDSB stock’s 52-week price range has touched low of $1.30 and a $13.48 high. Its shares traded higher over the last trading session, gaining 15.78% on 06/18/21. The shares fell to a low of $10.16 before closing at $11.52. Intraday shares traded counted 4.01 million, which was -138.77% lower than its 30-day average trading volume of 1.68M. PDSB’s previous close was $9.95 while the outstanding shares total 22.26M.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Investors have identified the Biotechnology company PDS Biotechnology Corporation as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $274.29 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
PDS Biotechnology Corporation (PDSB) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 27.26 million total, with 2.93 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -0.79 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on PDSB sounds very interesting.
Is the stock of PDSB attractive?
In related news, Director, Glover Steve C bought 5,882 shares of the company’s stock in a transaction that recorded on Jun 15. The purchase was performed at an average price of 8.50, for a total value of 49,997. As the purchase deal closes, the Director, Ali-Jackson Kamil now bought 11,764 shares of the company’s stock, valued at 99,994. Also, Chief Financial Officer, VAN VOORHEES SETH bought 17,647 shares of the company’s stock in a deal that was recorded on Jun 15. The shares were cost at an average price of 8.50 per share, with a total market value of 150,000. Following this completion of disposal, the Director, Freitag Gregory Gene now holds 5,882 shares of the company’s stock, valued at 49,997. In the last 6 months, insiders have changed their ownership in shares of company stock by 26.27%.
6 out of 6 analysts covering the stock have rated it a Buy, while 0 have maintained a Hold recommendation on PDS Biotechnology Corporation. 0 analysts has assigned a Sell rating on the PDSB stock. The 12-month mean consensus price target for the company’s shares has been set at $17.00.
